
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is currently undervalued based on the offered purchase price of $21.80 per share by Garda Therapeutics, which reflects a potential upside for investors. However, potential risks such as delays in the transaction or regulatory issues could impact the realization of this value and should be carefully considered. Additionally, the recent impairment of intangible assets by $40932736 highlights the potential volatility in the company's financials and emphasizes the need for caution in investing in this stock.
Bears say
Assertio Hldgs is being sold to privately-held Garda Therapeutics for $18 per share, representing a 46.6% premium to the 30-day unaffected volume-weighted average price and a 21.1% premium to Garda's initial offer. This decision comes after multiple parties were considered during Assertio's "window-shop" period, indicating a lack of confidence in its core products. Additionally, the company's recent reverse stock split and loss on impairment of intangible assets further highlight its financial struggles.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares